New pill shows promise in battling advanced prostate cancer

NCT ID NCT07172126

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 25 times

Summary

This study tests a new oral drug, TQB3201, in people with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The drug works by breaking down the androgen receptor, which fuels cancer growth. The trial aims to find the safest dose and check if the drug can slow the disease. About 291 participants will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cancer Hospital Affiliated to Chongqing University

    Chongqing, Chongqing Municipality, 400000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Cancer Hospital Affiliated to Fudan University

    Shanghai, Shanghai Municipality, 201321, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Fifth Affiliated Hospital of Sun Yat-sen University

    Zhuhai, Guangdong, 519000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.